OSTEOPOROSIS

ÁCIDO IBANDRÓNICO
BIBLIOGRAFíA
1. McClung M, Harris S, Miller P, Bauer D, Davidson S, et al. Bisphosphonate Therapy for Osteoporosis:
Benefits, Risks, and Drug Holiday. Am J Med 2012 ;126: 13-20
2. ParK , Hwang S,Jeon O, Moon H,Byun Y. Enhanced Oral Absorption of Ibandronate via Complex Formation
with Bile Acid Derivative. J Pharm Sci 2013; 102: 341–46
3. Frampton J. Perry C. Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis.
Drugs 2008 ; 68 (18): 2683-2707
4. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H,
Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North
America and Europe (BONE) Effects of oral ibandronate administered daily or intermittently on fracture risk
in postmenopausal osteoporosis. J Bone Miner Res 2004 ;19(8):1241-9
5. Vestergaard P, Mosekilde L, Langdahl B. Fracture prevention in postmenopausal women. Evidence
2011;05:1-36
6. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L,
Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD. Efficacy
and tolerability of oncemonthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the
MOBILE study.Ann Rheum Dis 2006;65(5):654-61
7. Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R,
Stakkestad JA, Lakatos P. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE longterm
extension study. Osteoporos Int 2012 Jun;23(6):1747-56
8. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg
D, Hughes C, Mairon N, Masanauskaite D, Reid DM,Delmas PD, ReckerRR.Efficacy and tolerability of
intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J
Rheumatol 2008;35(3):488-97
9. Miller PD, Epstein S, Sedarati F, ReginsterJY.Once-monthly oral ibandronate compared with weekly oral
alendronate in postmenopausal osteoporosis: results from the head-to head MOTION study. Curr Med Res
Opin 2008 ;24(1):207-13
10. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL.Risk of fracture in
women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate
Efficacy (VIBE) database fracture study. Bone 2009 ;44(5):758-65
11. Bala Y, Kohles J, Recker R, Boivin G. Oral Ibandronate in Postmenopausal Osteoporotic Women Alters
Micromechanical Properties Independently of Changes in Mineralization. 2013 Calcif Tissue Int 92:6–14
12. Emkey R, Koltum W, Beusterian K, et al. Patient preference for once month ibandronate versus once weekly
alendronate in a randomized open label cross over trial: the Bonviva Alendronate trial in osteoporosis
(BALTO). Curr Med Res Opin 2005;21(12): 1895-903
13. Hadji P, Minne H, Pfeifer M, et al.Treatment preference for monthly oral ibandronate in women with post
menopausal osteoporosis. A randomized cross over study (BALTO II). Jointh Bone Spine 2008; 75(3):30310
14. Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R.Patient satisfaction in
postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J
Womens Health (Larchmt). 2009 ;18(7):935-43
15. Curtis J, Yun H, Matthews R, Saag K, Dwlzell E. Adherence With Intravenous Zoledronate and Intravenous
Ibandronate in the United States Medicare Population. American College of Rheumatology 2012;64(7) :
1054–60
16. Bianchi, G. Czerwinski, E. Kenwright, A. Burdeska, A. Recker, R. Felsenberg, D.(2012).Long-term
administration of quarterly IV ibandronato is effective and well tolerated in postmenopausal osteoporosis:
5-year data from the DIVA study long-term extension.Osteoporos Int 23:1769–1778
OSTEOPOROSIS 2015 223